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Infection is a common cause of morbidity and mortality after liver
transplantation. Risk factors relate to transplantation factors,
donor and recipient factors. Transplant factors include ischaemia-
reperfusion damage, amount of intra-operative blood transfusion,
level and type of immunosuppression, rejection, and complica-
tions, prolonged intensive care stay with dialysis or ventilation,
type of biliary drainage, repeat operations, re-transplantation,
antibiotics, antiviral regimen, and environment. Donor risk
factors include infection, prolonged intensive care stay, quality of
the donor liver (e.g. steatosis), and viral status. For the recipient
the most important are MELD score >30, malnutrition, renal
failure, acute liver failure, presence of infection or colonisation,
and immune status for viruses like cytomegalovirus. In recent
years it has become clear that genetic polymorphisms in innate
immunity, especially the lectin pathway of complement activation
and in Toll-like receptors importantly contribute to the infection
risk after liver transplantation. Therefore, the risk for infections
after liver transplantation is a multifactorial problem and all
factors need attention to reduce this risk.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Orthotopic liver transplantation (OLT) has become a routine operation. One- and ﬁve-year patient
survival is around 90% and 80%, respectively. A major cause of mortality and morbidity after OLT is
infection, which occurs in up to 80% of the patients. Bacterial infections are most frequent (70%),ax: þ31 71 5248115.
.hoek@inter.nl.net (B. van Hoek).
Elsevier OA license.
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due to immunosuppression, often leading to delayed diagnosis. Both donor and recipient factors as
well as aspects related to the transplant operation contribute to the risk of infection after OLT. Recently
genetic polymorphisms in the innate immune system, from both donor and recipient, have been
identiﬁed as important risk factors for infection after OLT. The known risk factors for infection after OLT
will be discussed.Transplant factors
The timing of infections after OLT is shown in Table 1 [3–5], divided in early, intermediate (immune
suppression related) and late infections. Factors directly related to the OLT procedure contributing to
the risk of infection can be either surgical technical issues, but can also be preservation-related or graft-
related factors (Table 2). The rate of contaminated preservation ﬂuid varies among centres and regions
[6]. Peri-operative antibiotics will usually treat this, but culture-guided therapy sometimes is required
[7]. Particularly the amount of intra-operative blood transfusion is related to the risk of infection
immediately after OLT, both from the abdomen and other sources [2,8]. Initial poor graft function
carries an increased infection risk. Partial hepatic necrosis, e.g. due to hepatic artery thrombosis, can
lead to abscesses and bile duct injury with bacterial cholangitis. Abdominal ﬂuid collections can
become infected after OLT and need meticulous attentionwith imaging and diagnostic punctures. Both
anastomotic and non-anastomotic biliary strictures (NAS) increase the risk of cholangitis. These are
frequent complications and NAS more frequently occurs after non-heart-beating (NHB) donation
(¼DCD: deceased from cardiac death) [9]. Longer ischaemia times and genetic factors contribute to the
risk of NAS, and thus indirectly contribute to the risk of infection after OLT [10]. Biliary leakage can lead
to infected biloma, and this is seen more often with the use of a T-tube and bile duct ischaemia,
whether or not due to hepatic artery stenosis or thrombosis [11]. The risk of surgical site infection is
increased in the case of choledocho-jejunostomy [12]. In addition, indwelling catheters, invasive
interventions, and prolonged dialysis or ventilation increase the risk of bacterial infection [3]. The
antibiotic regimen around OLT has impact on the infection risk. Recent studies recommend oral
selective digestive decontamination (SDD) during stay in the ICU [13,14]. Studies on SDD in OLT show
a decrease in gram-negative bacterial infection, with an increased risk for gram-positive infection and
resistance and a questionable net effect [15]. Extensive use of antibiotics poses the patient at risk for
Clostridium difﬁcile or fungal infection. Fungal prophylaxis decreases this latter risk but appears to be
only justiﬁed in high-risk patients [3]. Risk factors for invasive candidiasis apart from heavy immu-
nesuppression are prolonged or repeat operations and re-transplantation, high transfusion require-
ment, previous Candida colonisation or renal failure after OLT, and a choledocho-jejunostomy. For
Aspergillus species the risk factors are similar plus fulminant hepatic failure, CMV disease and a pro-
longed ICU-stay [3].Table 1
Timing of different infections after liver transplantation [3,4].
First month
Surgical site, abdomen (infected ascites, abscesses, cholangitis), blood stream, urinary system, respiratory tract,
Clostridium difﬁcile colitis, herpes, Candida.
Between one and six months after OLT
Opportunistic infections, often related to over-immunosuppression (e.g. after rejection): a.o.
CMV (especially Dþ/R serostatus), EBV, HSV 6 and 7, Aspergillus species, Pneumocystis jirovecii,
Nocardia, tuberculosis, endemic mycoses, toxoplasma gonddi.
Bacterial cholangitis in case of biliary strictures.
Hepatitis C virus recurrence.
More than six months after OLT
Community-acquired, especially airway and urine tract in addition to opportunistic infections like varicella-zoster.
Bacterial cholangitis in case of biliary strictures.
Hepatitis C virus recurrence.
More infections in case of graft dysfunction, biliary strictures or recurrent rejection.
Table 2
Risk factors for infection after liver transplantation.
Transplant factors
Ischaemia times, ischaemia-reperfusion damage
Infected preservation ﬂuid
Amount of intra-operative blood transfusion
Level and type of immunosuppression (e.g. anti-CD25)
Additional immunosuppression for rejection
Indwelling catheters, deep lines
Complications like primary non-function, hepatic
artery thrombosis, necrosis, biliary strictures
Prolonged ICU-stay, dialysis, prolonged ventilation
Type of biliary drainage (Roux-en-Y, T-tube)
Repeat operations and re-transplantation
Antibiotic regimen
Viral prophylaxis and monitoring
Environment (other infected patients, building activity,
hygienic measures)
Recipient
Underlying condition of the recipient, i.e. malnutrition
Co-morbidity, e.g. diabetes, obesity, COPD, renal
failure and dialysis
Colonisation with S. aureus or resistant organisms
Prolonged hospital stay and catheters before OLT
Acute liver failure
CMV-status and disease (risk for other infections)
Presence of hepatitis B or C virus or HIV
MELD score >30
Recipient age
Previous immunosuppression (autoimmune hepatitis;
re-transplantation)
Previous infection (esp. airway, urine tract)
Immune status for viruses
Male recipient receiving male donor liver
Hygienic measures
Travelling
Genetic polymorphisms in innate immunity
Lectin pathway of complement activation in donor and
donor/recipient mismatch (MBL2, ﬁcolin2, MASP2)
Toll-like receptors in the recipient
Donor
Infection in donor
Prolonged ICU-stay
Quality of the liver graft (e.g. marginal graft)
Viral status
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Immunosuppressive treatment of rejection increases the risk of infection, including CMV reac-
tivation. If possible the level of immunesuppression, especially mycophenolate mofetil or azathioprine,
is reduced during CMV primo-infection or CMV-recurrence. During a severe infection or if EBV-DNA
becomes detectable, reduction of immunesuppression may be needed in order to control the infec-
tion, accepting the risk that later on rejection occurs requiring additional immunesuppression. Siro-
limus is associated with less cytomegalovirus infections than calcineurin inhibitors, but can – if used
early – lead to wound dehiscence and infection [16,17]. While allowing late introduction of calcineurin
inhibitors and thus sparing renal function, anti-thymocyte globulin may increase infection risk [18].
When a steroid-free regimen with anti-CD25 is compared to a regimen with prednisolone without
anti-CD25, the infection rate in the regimen with anti-CD25 (basiliximab) is lower in two studies
[19,20], similar in two [21,22] and increased in one study [23], with no differences in hepatitis C
recurrence.Recipient factors
A poor condition of the recipient increases the risk for infection: MELD score &gt;30, ICU-stay>48 h
prior to transplantation, recipient age, re-transplantation, predicted post-transplant dialysis or prob-
ability of reoperation are risk factors for infection (Table 2) [24]. Malnutrition is also a risk factor. Co-
morbidity like cystic ﬁbrosis or chronic bronchitis is known to increase the risk for pulmonary infec-
tion. Immunosuppression before OLT is a risk factor for infection and mortality, like – especially above
the age of 50 years – in autoimmune hepatitis [25]. A prolonged (>1week) pre-transplant hospital stay,
long-term intravenous catheters, and ascites before transplantation were found to be associated with
infection after OLT [26]. Obesity and diabetes appear to contribute to the risk of post-OLT wound
infections [17]. Gender plays a role in the susceptibility for many, but not all, infections and may be
related to the inﬂuence of sex hormones and gender differences in innate immunity [27]. Asmentioned
below, we and others showed that a male recipient of a male liver is at higher risk for bacterial
infections than the other combinations of donor and recipient sexes after OLT. If a recipient is colonised
B. van Hoek et al. / Best Practice & Research Clinical Gastroenterology 26 (2012) 61–7264with MRSA or ESBL bacteria or if the recipient is infected with C. difﬁcile, isolation measures are
important to protect the other (transplant) patients. Environmental factors like building activity in the
hospital (risk for Aspergillus fumigatus) or inadequate handwashing by personnel can also be risk
factors for transferring infections to an OLT recipient. Treatment of Staphylococcus aureus colonisation
can decrease morbidity after OLT [28,29].
Hepatitis B
In the past hepatitis B virus (HBV) present at OLT almost universally led to recurrence after OLT,
often leading to graft failure and recipient death. The long-term administration of anti-HBV immu-
noglobulins (HBIG) during and after OLT led to a substantial reduction of HBV recurrence, lamivudin
further reduced this problem, and the combination allowed OLT to be performed with <5% recurrence
[30,31]. HBV-DNA level at OLT determines the risk of recurrence evenwith prophylactic treatment [32].
The addition of adefovir dipivoxil to lamivudin allowed late withdrawal of HBIG in many patients
[33,34]. More recently, entecavir and tenofovir further reduced HBV recurrence after OLT and also
allowed treatment of lamivudin-resistant patients [35,36]. Even entecavir monotherapy was able
to prevent HBV recurrence [37]. Recipients of a donor liver with anti-HBV core protein positivity can
develop HBV after OLT if they are not immune, therefore such recipients also need HBV
prophylaxis [38].
Hepatitis C
Both in the USA and Europe hepatitis C virus (HCV)-related liver disease has become one of the
leading OLT indications. If HCV RNA is present at the time of OLT it persists after OLT. In about 60% of
patients this leads to more or less severe chronic active hepatitis. These patients can have an accel-
erated development of cirrhosis. As in HBV, patients transplanted with HCV can also develop chole-
stasis and rapid liver failure within weeks after OLT. Co-infection of HBV, HCV genotype 1, rejection
therapy, recipient age over 49 years, higher donor age, a steatotic or otherwisemarginal donor liver and
no HCV therapy were risk factors for severe recurrence in different studies [39]. No clear differences in
HCV recurrence existed between different induction immunosuppressive therapies [40]. Ideally HCV is
treated before OLT, but often this is not tolerated. Addition of telaprevir or boceprevir improves the
results of HCV treatment in patients before OLT. Studies with combinations of HCV protease and
polymerase inhibitors are underway, even without peg-interferon and ribavirin. HCV recurrence after
OLT can be treated with peg-interferon and ribavirin with a sustained overall viral response (SVR) rate
of 35%, which is lower than in non-transplant HCV patients. The interleukin-28B TT polymorphism is
associated with more severe histological HCV recurrence after OLT [41]. While the outcome of OLT for
HCV in African American patients and other races is similar [42], an African American patient with HCV
receiving a liver from a Caucasian donor also has a higher risk of severe HCV recurrence [43]. Poly-
morphisms in Toll-like receptor 3 may inﬂuence the development of rejection after OLT, when HCV is
present [44]. After OLT use of HCV protease inhibitors can lead to extreme elevations of levels of
tacrolimus and ciclosporin, and studies on combination therapy with peg-interferon, ribavirin and
a HCV protease inhibitor and regimes without interferon after OLT are awaited [45].
HIV
In the past patients with human immunodeﬁciency virus (HIV) were excluded fromOLT. Nowadays,
with the use of highly active anti-retroviral therapy (HAART) HIV replication can be suppressed, and if
CD4 lymphocyte counts are normal and no resistance to HAART exists OLT is possible in some patients
with end-stage liver disease in HIV. These patients are still more prone to infections after OLT than
other recipients and both HAART resistance and drug interactions need a lot of attention. Patients with
HIV and HBV can have an excellent outcome after OLT [46]. In a meta-analysis of liver transplant
outcomes in HIV-infected patients those with HBV had a better outcome than those without HBV,
while patients without detectable HIV-load at OLT did better than those with detectable HIV-load,
while in this study presence of HCV was not a predictor of outcome [47]. However, most authors agree
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a worse outcome after OLT in HCV-infected HIV-patients than in HIV-patients without HCV [48].Herpes viruses
The donor and recipient immune status for viruses are important risk factors for viral infections.
One of the most important viral infections after OLT is cytomegalovirus (CMV) infection: if a donor is
IgG anti-CMV positive and the recipient is IgG anti-CMV negative a CMV primo-infection almost
universally occurs in the recipient. Since, especially in the acute phase after OLT, this can lead to severe
morbidity and even mortality, prophylaxis with valganciclovir is used for this donor positive/recipient
negative (Dþ/R) CMV-status combination. Most centres use three to six months of valganciclovir
prophylaxis in this situation [49], and if the primo-infection then becomes manifest it is milder and the
recipient is out of the acute phase after OLT. In renal transplantation less CMV infection and disease
occurs if six instead of three months of valganciclovir prophylaxis is given. In the ﬁrst year after OLT
frequent monitoring of CMV-DNA by PCR in blood is indicated. In case CMV-DNA becomes positive
after prophylaxis in a Dþ/R combination (val)ganciclovir is started preemptively. In general, no
prophylaxis with (val)ganciclovir is used in IgG anti-CMV positive recipients [50], although some of
these patients may require more intensiﬁed CMV-DNA monitoring or prophylaxis.
EBV primo-infection or reactivation in the recipient is possible and can lead to post-transplant
lymphoproliferative disease (PTLD) in the OLT recipient. This can range from mononucleosis to frank
non-Hodgkin lymphoma. Treatment includes cessation of all immunosuppression except predniso-
lone, and administration of anti-CD20 in case of a B-cell PTLD. It is advisable tomonitor EBV-DNA in the
ﬁrst year post-OLT, and in case of a positive and rising EBV-DNA to at least decrease the immuno-
suppression. Often EBV-DNA becomes undetectable after decreasing the amount of immunosuppres-
sion. The donor/recipient status for EBV, the amount of activated natural killer cells and certain
underlying autoimmune disorders were found to increase the risk for PTLD [51].
The degree of immunosuppression and D/R status of IgG to other viruses like HSV 1,2, 6,7,8 and VZV
determines the risk of developing disease from these viruses. Especially HSV 1 and 2 and VZV can be
treated by (val)aciclovir. Most centres do not use prophylaxis for these viruses, but they use early
treatment if required [52–55].
Donor factors
Currently infection of a donor leads to morbidity and mortality in approximately 1% of transplant
recipients. Rapid nucleic acid testing for microbial infections in the donor might lead to higher
acceptance rates of high-risk donors [56]. Especially with a longer stay of the donor in the hospital the
risk to acquire a nosocomial infection increases. Bacterial infections in the donor are often treated with
antibiotics in donor and recipient. Some unknown infections in the donor, like dengue or hepatitis E
[57], may endanger a transplant recipient. Insufﬁciently treated or undetected infections in the
recipient more often than donor infections lead to sepsis after OLT [58]. The quality of the graft (e.g.
steatosis, donor age) relates to graft function, ICU and hospital stay and infectious complications.Genetic polymorphisms in the innate immune system
Since adaptive immunity is suppressed by the immunosuppressive medication, the recipient
becomes dependent on the innate immune system. This includes pattern recognition receptors (PRRs)
that recognise pathogen-associated molecular patterns (PAMPs) on microorganisms. The innate
immune system can then kill the pathogen directly in a lymphocyte-independent manner or activate
adaptive immunity. In several pathways of innate immunity single nucleotide polymorphisms (SNPs)
are known. In some other categories of immunosuppressed patients, e.g. bonemarrow recipients, some
of these polymorphisms were associated with an increased occurrence or severity of infection. This led
to the hypothesis that such SNPs might inﬂuence the risk and severity of infection after OLT.
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Lipopolysaccharide from gram-negative bacteria is mainly recognised by Toll-like receptor 4 (TLR4).
However, in a cohort from the Mayo Clinic no signiﬁcant associations were found between the TLR4
SNPs D299G and T399I and the risk and outcome of gram-negative infections after OLT [59]. Toll-like
receptor 2 (TLR2) is the major receptor for gram-positive bacterial cell wall components like pepti-
doglycan and lipoteichoic acid. The common R753Q SNP in the TLR2 gene results in defective intra-
cellular signalling and impaired cytokine secretion in response to peptidoglycan, lipopeptides, and
other known ligands. The mutation has been suggested to increase to risk of bacterial and viral
infections and was found to inﬂuence the risk for and outcome of cytomegalovirus and hepatitis C
infection after OLT [60–62]. The homozygous TLR2 Arg753Gln (R753Q) polymorphism impairs
recognition of HCV core and NS3 proteins and was shown to be associated with allograft failure and
mortality after OLT for chronic HCV [60,62]. The R753Q polymorphism also paralyses recognition by
TLR2-mediated immune signalling in cells exposed to CMV glycoprotein B [61]. Patients homozygous
or heterozygous for the TLR2 R753Q SNP had a higher CMV load and more CMV disease than OLT
recipients without this SNP [63]. Recently a PCR was developed to detect the N284I and the L412F SNPs
in the TLR3 gene that also plays a role in the defence against viruses, and clinical studies in relation to
TLR3 polymorphisms are awaited [64].
Lectin pathway of complement activation
The lectin pathway of complement activation is an evolutionary conserved defence against
microorganisms [65]. It includes mannan-binding lectin (MBL), ﬁcolin-2 (FCN2) and MBL-associated
serine protease 2 (MASP2). These proteins are almost exclusively liver-derived and crucial effectors
of the innate immune system in the defence against pathogens. Lectins are humoural PRRs that
recognise carbohydrate-motifs on microorganisms and elicit innate immunity. These lectins cooperate
with phagocytes and other humoural factors, including complement [66,67]. Polymorphisms in the
lectin pathway determine its functional activity and are quite common. Mannan-binding lectin (MBL)
and ﬁcolin-2 (FCN2) both can activate the MBL-associated serine protease 2 (MASP2) [68]. FCN2 has
similarities in structure and function to MBL and its preferential binding target is N-acetyl-glucos-
amine, a constituent of bacterial peptidoglycans and a major component of their cell wall [69,70].
Activated MASP activates the complement cascade and leads to opsonisation of microorganisms for
phagocytosis or leads to formation of a complement membrane-attack complex (Fig. 1), which leads to
‘holes’ in the bacterial wall resulting in death of the pathogen [71–73]. It had been shown that SNPs in
the exon1 region of the MBL gene (MBL2) interfere with the oligomerization of the protein and
polymorphisms in the promoter regions alter the rate of synthesis of the protein, leading to changes in
avidity and protein level of MBL respectively, resulting in MBL deﬁciency [74–76]. Ficolin-2 (FCN2)
SNPs in the carbohydrate-recognition domain encoding region are associated with decreased (FCN2-B)
or increased (FCN2-C) ligand binding of ﬁcolin-2 compared to wild-type ﬁcolin-2 (FCN2-A) [77].
MBL deﬁciency is associated with more and more severe infections in HIV infection, bone marrow
transplantation, pancreatic and renal transplantation, but not in several other conditions, such as
pneumococcal infections in randomly included patients, and it may confer protection against tuber-
culosis [78–80]. However, MBL deﬁcient patients receiving a pancreas–kidney transplantation had
better outcomes because of some protection against ischaemia-reperfusion injury and rejection [81].
Two polymorphisms in the MASP2 gene lead to a functional defect in the protease [82]. One SNP leads
to the inability to activate complement [83,84], the other SNP is located in the control protein domain2
of MASP2, which is important in stabilising the structure of the serine protease domain [85], and is
essential for cleavage of complement C4 [86]. Since MBL, ﬁcolin-2 and MASP2 are almost exclusively
produced by the liver their impact in OLT is of particular importance [87]. Our group recently showed
that polymorphisms in the lectin pathway of complement activation are important risk factors for
bacterial infection post-OLT. Transplantation of a MBL deﬁcient donor liver into a MBL sufﬁcient
recipient results in rapid decrease in MBL blood levels, while the functionally important MBL2 SNP in
the donor that resulted in low blood levels was also associated with bacterial infections after OLT [88].
This ﬁnding was then conﬁrmed by others [89,90]. Since the ﬁcolin pathway may compensate for
Fig. 1. The lectin pathway is activated when either mannose-binding lectin (MBL) or ﬁcolin-2 binds to carbohydrate structures or
PAMPs which are present on a large number of pathogens. Upon binding, the associated serine protease MASP2 is responsible for
activation of the complement cascade. This will lead to opsonization for phagocytosis and the formation of a membrane-attack
complex, both resulting in the killing of the pathogen. Modiﬁed from: Dommett et al. Mannose-binding lectin in innate immunity:
past, present and future. Tissue Antigens (2006) 68: 193–209.
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include all known functional SNPs in the lectin pathway of complement activation, including MBL2,
FCN2 and MASP2 [91]. Recipients receiving a donor liver with mutations in all three components, i.e.
MBL2 (XA/O or O/O), FCN2þ6359T, and MASP2þ371A, had a cumulative risk of bacterial infection of
75% as compared to only 18%with wild-type donor livers, an observation conﬁrmed in a second cohort.
In addition a genetic (mis)match between donor and recipient conferred a two-fold higher infection
risk for each separate gene. The more SNPs leading to a deﬁcient phenotype (with low MBL level and
low-binding ﬁcolin levels in the recipient), the higher the risk for bacterial infection (Fig. 2). This wasFig. 2. Cumulative incidence of clinically signiﬁcant infection after orthotopic liver transplantation, according to donor lectin
pathway intergenic haplotype. Ref. [92].
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recipient (mis)match proﬁle independent from other risk factors gender and antibiotic schedule. In
addition, patients with the indicated lectin pathway gene polymorphisms and infection had a six-fold
higher mortality, of which 80% was infection-related [92].
The relationship between cytomegalovirus (CMV) and MBL in solid organ transplantation had
been studied mainly in kidney transplantation [78,93,94], and only in a small number of patients after
OLT [95]. We investigated the complete MBL–ﬁcolin–MASP gene proﬁle in relation to CMV infection
after OLT. It became clear that polymorphisms in the lectin pathway of complement activation also
increase the risk of CMV disease. Combined analysis of variant MBL2 (XA/O or O/O) and wild-type
FCN2 (FCN2-A) polymorphisms in the donor liver showed an independently associated increased
risk of CMV infection for either and both genotypes. This effect was especially strong in IgG anti-CMV
donor negative/recipient positive (D/Rþ) patients. Moreover, a genetic donor–recipient mismatch
for MBL2 and FCN2 increased the CMV risk independently, also combined, and also particularly in
CMV D/Rþ patients. For MBL the highest risk for CMV infection was in MBL sufﬁcient recipients of
a MBL deﬁcient donor liver. In addition, a FCN2-C (high-afﬁnity) donor liver reduced the chance for
CMV infection in a FCN2-A recipient as opposed to the other FCNs genotype combinations. Again,
there was a stepwise increase in CMV infection risk with the gene proﬁle of the donor and the
combined MBL2 and FCN2 donor-recipient mismatch proﬁle, independent from donor–recipient CMV
serostatus, also at increasing CMV (re)infection cut-off values of CMV positivity [96]. These data
indicate that a link exists between several components of the lectin pathway of complement acti-
vation and the initial immune response to bacteria and CMV after OLT. The association of MBL2 SNPs
with CMV and with bacterial infections was similar after OLT. However, with bacterial infections an
association with FCN2-B and with MASP2 SNPs was found, while for CMV infection FCN2-C was
important and no relation with MASP2 was found [96]. This illustrates differences in innate immune
defence against bacterial and viral (CMV) pathogens after OLT [92,96]. CMV regulates immuno-
modulatory genes, that also change innate immunity in favour of CMV survival, e.g. inhibition of NF-
kB leading to decreased cytotoxicity, and inhibition of dendritic cells and their functionality [97–99].
This might also explain why CMV infection or reactivation increases the susceptibility to bacterial and
pneumocystis infection. Complement activation is potentially detrimental to the host and is kept in
place by inhibitors. CMV is able to upregulate the expression of host-encoded (surface) complement
inhibitors [100], and counteracts complement activation by incorporation of host cell-derived
complement regulatory proteins CD55 and CD59 [101]. As mentioned, TLR2 Arg753Gln gene
polymorphism is associated with CMV replication after OLT [63]. MBL is able to interact with TLR2 in
the phagosome to initiate pro-inﬂammatory signalling [102], and therefore SNPs in both may affect
this signalling and changed immunity against CMV after OLT. A subsequent mechanism by which
MBL could be involved in immunity against CMV is that the intracellular interaction of its isoform I-
MBL with CMV glycoproteins may disrupt CMV virion assembly or formation, restricting CMV
replication [103].
A possible clinical application of our ﬁndings could be to screen for recipient and donor MBL2, FCN2
andMASP2 risk alleles. Subsequently one could intensify the antibiotic strategy or antiviral prophylaxis
and more closely monitor high-risk patients. It is unknown if supplementation of recombinant MBL or
ﬁcolinwill decrease the infection risk post-OLT. It has been shown that recovery of opsonic activity lags
behind recovery of MBL serum levels [104]. A study with recombinant MBL in OLT was terminated by
the sponsor, as yet for unclear reasons.
It has become clear that certain innate genetic proﬁles of donor and recipient are important risk
factors for infections after OLT [105]. Indeed, as shown, they seemmore important than some clinical or
environmental factors. Other disturbances in innate immunity may also play a role. This may include
changes in – for instance – other Toll-like receptors, Nod-receptors, or RIG-1 like receptors [106].
Recognition of PAMPs by PRRs triggers a cascade of downstream signalling leading to an array of anti-
microbial immune responses by cytokines, chemokines and type I interferons, and these responses
may also be changed due to polymorphisms in some recipients [106]. Crosstalk between innate and
adaptive immunity may also be affected. More investigation into this area is urgently needed. If the
genetic make-up of donor and recipient is known this may lead to more personalised prophylaxis
around OLT.
Practice points
 Many transplantation-related, recipient and donor factors are involved in the risk for infec-
tion after liver transplantation.
 Genetic polymorphisms in innate immunity, e.g. in recipient toll-like receptors, and in both
the donor and recipient lectin pathway of complement activation have an important impact
on the infection risk in the liver transplant recipient.
Research agenda
 The inﬂuence of polymorphisms in the innate immune system on the infection risk after liver
transplantation needs to be further elucidated
 Prospective controlled studies are needed to investigate the role of intensiﬁed monitoring
and anti-microbial prophylaxis in recipients at high-risk for infectious complications.
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